bcdiabetes.ca
Patient Care + Research + Clinical Trials

Dr. Tom Elliott MBBS, FRCPC
Medical Director

400 - 210 W Broadway
Vancouver, BC
V5Y 3W2 Canada

phone: 604.683.3734
fax: 604.628.3821
email: moa@bcdiabetes.ca

Type 1 diabetes clinical trials

Pre-Type 1 diabetes (stage 2, no symptoms positive autoantibodies)

Baricade-delay RCT of baricitinib in stage 2 (pre-clinical) Type 1 diabetes age 1-36 years

Within 100 days of diagnosis of clinical symptomatic T1D (stage 3)

FABULINUS: age 12-21 beta cell salvage & rejuvenation within first 100 days of dx of Type 1

OBTAIN: age 18-35 years nanobody Rx for preservation of beta cells <90 days of dx of Type 1

Baricade-preserve: age 1-36 baricitinib in preservation of beta cells < 100 days (starting early 2026)

Recruitment completed 2024-Dec-04: **UST1D2**: ustekinumab age 18-35 beta cell salvage & rejuvenation < 100 days of dx of Type 1. 58 BCDiabetes clients participated.

Within first 12 months of diagnosis

Nothing currently….

5 years or more after diagnosis

Zucara: age 18-75 nocturnal hypoglycemia duration > 5 year (somatostatin antagonist)

Islet cell transplantation (typically > 5 years post diagnosis)

BCDiabetes has been in early discussion with Sana Pharmaceuticals about the tremendously exciting work published 2025-Aug-4 by Per-Ola Carlsson's group in Uppsala, Sweden. The

Carlson group showed functional survival of allogeneic human beta cells without immunosuppression transplanted into the forearm of a 42 year old man living with Type 1 for 37 years. Sana's cell line was genetically engineered to not incite an immune response and is blood group O Negative, meaning that blood type-matching of potential recipients will not be necessary.

> Recruitment completed 2025-July-15: **Vertex 880** Islet Cell Transplant study at Vancouver General Hospital with Dr. Breay Paty as Principal Investigator. In this tremendously exciting study 10 of 12 subjects who received the Islet cell transplant required no insulin at the 12 month mark. Two BCDiabetes subjects have received this transplant (one in the original 12 and another in early 2025). Immunosuppression is required life-long. See published paper here.

BCDiabetes is helping recruit subjects for a related **Vertex 880**, using the same cell line described in the successful study above, but for individuals with type 1 diabetes who have undergone a kidney transplant. For more information contact Dr. Breay Paty, Dr. Ahsen Chaudry or the study coordinator Levina Ira ph 604 875 4111 ex 62178

> Study abandoned 2025-Mar-22 for lack of efficacy: **Vertex 264**: Islet cell transplant, age 18-65, T1 onset age < 40 yrs, duration of T1 > 5 years

Breakthrough T1D links for active clinical trials in T1D

Short URL = https://bit.ly/T1DCTs